Subsequently, it was found that a symmetrically structured NDGA derivative of Af23 could effectively inhibit FGFR1 kinase in a non-ATP competitive manner (IC50 = 1.4 μM) and had potent anti-cancer activity against human lung cancer in vitro and in vivo. The gene discussed is FGFR1; the disease is lung carcinoma.